Immune-mediated enterocolitis is inflammation affecting both the small and large intestines that occurs as a side effect of cancer immunotherapy. This condition develops when immune checkpoint inhibitor drugs, which help the body’s immune system attack cancer cells, also trigger an unwanted inflammatory response in the gastrointestinal tract, leading to diarrhea, abdominal pain, and sometimes serious complications.

How Immunotherapy Can Affect Your Digestive System

When you receive treatment with immune checkpoint inhibitors for cancer, these powerful medicines work by removing the brakes on your immune system. This allows your body to recognize and fight cancer cells more effectively. However, because this immune boost isn’t limited only to cancer cells, it can sometimes cause your immune system to attack healthy tissues throughout your body.^[1]

The goal of treating immune-mediated enterocolitis is to control the inflammation in your intestines while continuing your cancer treatment whenever possible. Doctors focus on reducing symptoms like diarrhea and pain, preventing serious complications such as intestinal perforation or severe bleeding, and helping you maintain adequate nutrition during recovery. Treatment decisions depend heavily on how severe your symptoms are and how quickly you respond to initial therapies.^[2]

Your healthcare team will categorize your condition based on severity, using a grading system that ranges from mild (grade 1) to life-threatening (grade 5). This grading helps determine whether you can continue immunotherapy, whether you need hospitalization, and what types of medications will work best. Early detection and prompt treatment significantly improve outcomes, which is why your cancer care team monitors you closely for digestive symptoms after starting immunotherapy.^[3]

The approach to managing immune-mediated enterocolitis combines several strategies. For mild cases, supportive care and dietary adjustments may be enough. More severe cases require medications that suppress the overactive immune response. Your medical team constantly balances controlling the intestinal inflammation against maintaining the cancer-fighting benefits of your immunotherapy drugs.^[4]

Standard Treatment Approaches

The first step when diarrhea develops during immunotherapy treatment involves ruling out infections. Your doctor will order stool tests to check for bacteria like Clostridioides difficile (a bacterium that commonly causes diarrhea), as well as viruses and parasites. This is crucial because treating an infection requires completely different medications than treating immune-mediated inflammation.^[5]

For patients with mild symptoms—fewer than four bowel movements per day above their normal baseline—supportive care often suffices. This includes drinking plenty of fluids to prevent dehydration, following a bland diet that’s easier on the intestines, and using anti-diarrheal medications like loperamide. Your immunotherapy treatment may continue without interruption if symptoms remain mild and manageable.^[3]

When symptoms become moderate (four to six extra bowel movements daily, or severe abdominal pain), treatment with corticosteroids—medications that reduce inflammation throughout the body—becomes necessary. The most commonly prescribed corticosteroid is prednisone or prednisolone, typically given at doses of 0.5 to 1 milligram per kilogram of body weight daily. Your immunotherapy drugs will likely be temporarily stopped while the inflammation is brought under control.^[7]

If you don’t improve within three to five days of starting corticosteroids, or if your symptoms are severe from the outset (more than seven extra bowel movements daily, severe pain, fever, or blood in stool), your medical team will add stronger immunosuppressive medications. The most frequently used is infliximab, a biologic drug that blocks a protein called tumor necrosis factor-alpha (TNF-alpha), which plays a key role in inflammation. Infliximab is given through an intravenous infusion, typically at a dose of 5 milligrams per kilogram of body weight.^[4]

Another biologic option is vedolizumab, which works differently from infliximab by targeting inflammation specifically in the digestive tract. Vedolizumab blocks certain white blood cells from entering the intestinal lining, thereby reducing inflammation where it’s happening. This medication may be preferred for patients who don’t respond to infliximab or who have conditions that make TNF-blockers risky. Both medications require multiple infusions over several weeks or months.^[3]

During treatment, your doctor will likely perform a colonoscopy—a procedure where a flexible tube with a camera is inserted through your rectum to examine your large intestine. This allows direct visualization of inflammation, ulcers, or other damage, and small tissue samples (biopsies) can be collected for laboratory analysis. The appearance of your intestinal lining and the specific patterns seen under the microscope help confirm the diagnosis and guide treatment decisions.^[7]

The duration of treatment varies considerably among patients. Some people respond quickly to corticosteroids and can taper off within a few weeks. Others require several months of immunosuppressive therapy. Your healthcare team will make decisions about restarting immunotherapy based on how well your intestinal inflammation has resolved and your overall cancer treatment needs.^[2]

Common side effects of corticosteroids include increased appetite and weight gain, mood changes ranging from irritability to euphoria, difficulty sleeping, elevated blood sugar levels that may require diabetes medications, increased blood pressure, and weakening of bones with prolonged use. Infliximab and vedolizumab can cause infusion reactions (fever, chills, rash during the medication administration) and increase infection risk. Rarely, infliximab may trigger new autoimmune problems or liver inflammation.^[10]

Innovative Treatments Being Studied in Clinical Research

Because some patients don’t respond well to standard corticosteroids and biologic drugs, researchers are actively investigating new treatment approaches for immune-mediated enterocolitis. These studies aim to find therapies that can quickly control intestinal inflammation while allowing patients to continue benefiting from their cancer immunotherapy.^[6]

One promising area of research involves fecal microbiota transplantation (FMT), a procedure where stool from a healthy donor containing beneficial bacteria is transferred into a patient’s digestive system. Scientists have discovered that the community of bacteria living in your intestines—your gut microbiota—plays a significant role in how your immune system behaves. Studies suggest that certain bacterial populations may protect against immune-mediated enterocolitis, while others may make it more likely to develop.^[11]

Clinical trials testing fecal microbiota transplantation have shown encouraging results. In these studies, patients with immune-mediated enterocolitis who hadn’t responded to standard treatments received donor stool transplants. Many experienced rapid improvement in their symptoms and were able to stop taking immunosuppressive medications while continuing their cancer therapy. The treatment works by restoring a healthier balance of intestinal bacteria that helps calm the overactive immune response. These trials are primarily being conducted at specialized cancer centers in the United States, and researchers are working to understand exactly which bacterial species provide the most benefit.^[6]

Another investigational approach involves using more targeted immunosuppressive medications that specifically block certain immune pathways without broadly suppressing the entire immune system. Researchers are studying drugs that inhibit specific cytokines—proteins that immune cells use to communicate—such as interleukin-6 (IL-6), interleukin-12 (IL-12), and interleukin-23 (IL-23). By blocking only the cytokines most responsible for intestinal inflammation, these therapies might control enterocolitis while preserving more of the cancer-fighting immune response. These studies are in Phase II, where effectiveness is being tested in small groups of patients.^[2]

Researchers are also investigating drugs that block white blood cell replication in very specific ways. One class being studied includes Janus kinase (JAK) inhibitors, which are small molecules that interfere with signaling inside immune cells. Unlike antibodies such as infliximab that are given intravenously, JAK inhibitors are pills taken by mouth, which many patients find more convenient. These medications have shown success in treating other inflammatory bowel conditions and are now being tested specifically for immune checkpoint inhibitor-related enterocolitis. Early results suggest they may work quickly to reduce intestinal inflammation.^[2]

Some clinical trials are examining whether starting preventive medications before enterocolitis develops can reduce its occurrence or severity. These studies involve giving patients probiotics (beneficial bacteria supplements) or anti-inflammatory drugs alongside their immunotherapy from the beginning of cancer treatment. The hypothesis is that establishing a healthier gut environment early might prevent the immune system from attacking the intestines. These preventive trials are in Phase II and III stages, comparing outcomes between patients who receive preventive treatments and those who receive standard monitoring.^[7]

Investigators are studying the role of specialized imaging techniques and blood tests to predict which patients are most likely to develop severe enterocolitis. These include measuring specific inflammatory markers like calprotectin and lactoferrin in stool samples, which indicate intestinal inflammation before severe symptoms appear. Some research centers are analyzing patients’ gut microbiota composition at the start of immunotherapy to identify high-risk bacterial patterns. If successful, these predictive tools could allow doctors to intervene earlier or adjust cancer treatment strategies before serious inflammation develops.^[7]

Research is also exploring whether the timing of immunotherapy administration affects enterocolitis risk. Some trials are testing modified dosing schedules or sequential (rather than simultaneous) administration of different checkpoint inhibitor drugs to maintain cancer treatment effectiveness while reducing intestinal side effects. These studies are primarily being conducted at major cancer centers across Europe and the United States, involving patients with various cancer types including melanoma, lung cancer, and kidney cancer.^[1]

Most Common Treatment Methods

• Corticosteroids
  • Prednisone or prednisolone tablets taken daily, typically at doses of 0.5 to 1 milligram per kilogram of body weight for moderate symptoms
  • Intravenous methylprednisolone for severe cases requiring hospitalization, usually given at 1 to 2 milligrams per kilogram daily
  • Gradual dose reduction over several weeks once symptoms improve to prevent relapse and withdrawal effects
• Biologic immunosuppressants
  • Infliximab infusions blocking tumor necrosis factor-alpha, administered intravenously at 5 milligrams per kilogram, typically given as a single dose or repeated at intervals
  • Vedolizumab infusions targeting gut-specific inflammation, given at 300 milligrams intravenously at specific intervals over several weeks
• Supportive care
  • Anti-diarrheal medications like loperamide for mild symptoms with fewer than four extra bowel movements daily
  • Dietary modifications including bland foods, adequate hydration, and avoidance of high-fiber or irritating foods
  • Electrolyte replacement to correct imbalances caused by diarrhea and poor absorption
• Experimental therapies in clinical trials
  • Fecal microbiota transplantation to restore healthy intestinal bacteria in patients not responding to standard treatments
  • JAK inhibitors taken as pills to block specific immune signaling pathways
  • Cytokine-blocking medications targeting interleukin-6, interleukin-12, or interleukin-23